The rationale behind this study stems from the underlying neuropathological and neurochemical commonalities observed between Alzheimer’s disease and certain neurodevelopmental disorders. While Alzheimer’s primarily affects aging populations with hallmark features of memory decline and executive dysfunction, autism spectrum disorder is characterized by pervasive developmental challenges in social interaction, communication, and repetitive behaviors, often coupled with cognitive deficits. Notably, shared aspects such as synaptic dysfunction, neuroinflammation, and neurotransmitter imbalances suggest potential overlapping mechanisms that could be modulated by similar pharmacological agents.

Employing a comprehensive scoping review framework, the research team systematically assessed existing literature for evidence of AD medications’ impacts on neurocognitive outcomes in ASD youth with low IQ. Alzheimer’s treatments, particularly cholinesterase inhibitors and glutamate receptor modulators, have well-documented efficacy in enhancing synaptic plasticity and cognitive function in adults, but their utility in pediatric populations with distinct neurodevelopmental profiles remains largely unexplored. By navigating through the intricacies of diverse clinical trials, observational studies, and case reports, the researchers sought to map the current knowledge landscape and identify promising directions for future clinical research.

At the core of the review lies a critical examination of cholinesterase inhibitors—drugs that increase levels of acetylcholine, a neurotransmitter pivotal for learning and memory. These agents, such as donepezil and rivastigmine, have revolutionized Alzheimer’s care by partially restoring cholinergic signaling pathways impaired in dementia. Intriguingly, cholinergic dysfunction has also been implicated in ASD, suggesting potential neurochemical targets that could yield cognitive benefits. Preliminary clinical data suggest heterogenous responses, ranging from subtle improvements in attention and executive function to minimal adverse events, thereby warranting cautious optimism.

Glutamatergic neurotransmission, another focal pathway in AD pharmacotherapy, has drawn attention for its dual role in synaptic plasticity and excitotoxicity. Memantine, an NMDA receptor antagonist, acts by modulating aberrant glutamate activity to protect neurons from damage while preserving cognitive function. Its off-label application in ASD has sporadically demonstrated enhancements in behavioral symptoms and adaptive functioning, though results remain inconsistent across studies. The review highlights the mechanistic underpinnings of memantine and analogous compounds that could recalibrate excitatory-inhibitory balance—often disrupted in autism—with potential downstream effects on cognition.

In addition to monotherapies, the interplay of combined pharmacological strategies is considered critical for optimizing neurocognitive outcomes. The multifaceted nature of ASD, compounded by low IQ, necessitates a nuanced approach that addresses diverse neural circuits and compensatory mechanisms. The review underscores the imperative for rigorous clinical trial designs incorporating robust cognitive assessments, biomarker analyses, and longitudinal follow-up to disentangle the precise contributions of AD medications in this context.

Importantly, the researchers emphasize the considerable ethical and developmental considerations intrinsic to pharmacological interventions in pediatric neurodevelopmental disorders. The potential for adverse effects on the developing brain, alongside the variability in individual neurobiology, mandates a judicious evaluation of risk-benefit ratios. The review advocates for stratified medicine approaches, leveraging genetic, neuroimaging, and neurophysiological data to tailor treatments and monitor efficacy and safety meticulously.

Highlighting gaps in the literature, the scoping review identifies a paucity of large-scale, randomized controlled trials explicitly targeting the ASD-low IQ cohort with AD medications. Most existing studies are limited by small sample sizes, heterogeneous methodologies, and primarily focus on behavioral outcomes rather than direct neurocognitive measures. This underscores an urgent need for high-powered, mechanistically informed clinical investigations to validate preliminary findings and elucidate treatment mechanisms.

Beyond pharmacology, the review contextualizes these findings within broader therapeutic landscapes, including behavioral interventions and supportive educational strategies. The integration of AD medications as adjunctive treatments could potentiate neuroplasticity and learning capacities, potentially enhancing the efficacy of comprehensive ASD programs. This aligns with emerging paradigms advocating for multimodal, interdisciplinary approaches to optimize functional outcomes in neurodevelopmental disorders.

Technological advances in biomarker discovery and neuroimaging are poised to accelerate progress in this domain. Functional MRI, PET scans targeting cholinergic and glutamatergic systems, and electrophysiological studies could provide unprecedented insights into drug action and neural circuitry alterations in response to therapy. The review calls for leveraging these tools to inform patient selection, dosing regimens, and treatment monitoring, ultimately prefacing precision medicine frameworks for ASD management.

In sum, this scoping review illuminates an innovative frontier at the intersection of neurodegeneration and neurodevelopment. It proposes that repositioning AD medications might open untapped therapeutic potentials for children and adolescents grappling with ASD and low IQ, a population confronting significant cognitive and adaptive challenges. While the evidence remains nascent and calls for robust future inquiry, this work forms a foundational reference point for clinicians, researchers, and stakeholders invested in advancing neurocognitive health across the lifespan.

This collaborative endeavor, integrating expertise from neuropharmacology, psychiatry, and developmental neuroscience, exemplifies the translational spirit essential for tackling complex brain disorders. It underscores the imperative to transcend traditional diagnostic silos and embrace cross-disciplinary explorations that may yield transformative benefits for vulnerable populations historically marginalized in clinical research.

As the neuroscience community grapples with the complexities of autism and cognitive impairment, this review catalyzes important conversations around innovative therapeutic repurposing. It invites bold hypotheses and methodologically rigorous investigations that could redefine standards of care and improve quality of life for children and adolescents navigating the intersecting challenges of ASD and intellectual disability.

Continued investment in this nascent field promises to uncover molecular and cellular insights with far-reaching implications, potentially shedding light on convergent neuropathological pathways across diverse neuropsychiatric and neurodegenerative disorders. By harnessing the lessons learned from Alzheimer’s pharmacotherapy, the search for effective interventions in autism may gain valuable momentum, ultimately enriching our understanding and treatment of complex brain dysfunction.

The implications of such research extend beyond immediate clinical outcomes, shaping policy decisions, educational frameworks, and societal perceptions around neurodiversity and cognitive health. This paradigm shift invites a more inclusive and mechanistically grounded approach to neurodevelopmental disabilities, fostering hope and tangible progress in an area long characterized by unmet needs and therapeutic challenges.

In conclusion, this scoping review stands as a testament to innovative scientific inquiry and the promise of interdisciplinary collaboration. By rigorously evaluating the potential of Alzheimer’s disease medications to enhance neurocognitive outcomes in children and adolescents with autism spectrum disorder and low IQ, it lays critical groundwork for future breakthroughs poised to transform clinical practice and quality of life for this underserved population.

Subject of Research: Neurocognitive effects of Alzheimer’s disease medications on children and adolescents with autism spectrum disorder and low IQ.

Article Title: Effect of Alzheimer’s disease medications on neurocognitive outcomes in children and adolescents with autism spectrum disorder and low IQ: a scoping review.

Article References:
Diamandis, N., van den Anker, J.N. & Denisova, K. Effect of Alzheimer’s disease medications on neurocognitive outcomes in children and adolescents with autism spectrum disorder and low IQ: a scoping review. Transl Psychiatry 15, 475 (2025). https://doi.org/10.1038/s41398-025-03655-2

Image Credits: AI Generated

DOI: 17 November 2025

Sepsis-associated encephalopathy is a severe and often fatal complication of systemic infection, characterized by acute brain dysfunction including delirium, cognitive impairment, and long-term neurological deficits. The pathogenesis of SAE has been largely obscure, but accumulating evidence implicates neuroinflammation and altered synaptic homeostasis as central factors. Through meticulous cellular and molecular interrogation, Wu, Zhang, Yu, and colleagues have elucidated that small intestinal γδ T17 cells actively promote SAE pathophysiology, thus opening new avenues for therapeutic exploration aimed at modulating peripheral immune influences on the brain.

γδ T cells are a unique T cell subset distinguished by their T-cell receptor, which is composed of γ and δ chains rather than the conventional αβ configuration. These cells are abundant in barrier tissues such as the gut and are known for their rapid and robust cytokine production, particularly interleukin-17 (IL-17). The relevance of γδ T17 cells, a subset specialized in IL-17 secretion, has predominantly been studied within the context of mucosal immunity and inflammatory disorders. However, their role in brain disease, especially in systemic inflammatory states like sepsis, had remained enigmatic until now.

The researchers employed a sophisticated murine model of sepsis to investigate how small intestinal γδ T17 cells influence SAE progression. Intriguingly, male mice exhibited a distinct exacerbation of neurological symptoms, concomitant with an increase in these gut-resident γδ T17 cells. Further analysis revealed that these cells activate the stimulator of interferon genes (STING) pathway, a central mediator of innate immune sensing of cytosolic DNA, which in turn upregulates the expression of complement component C1q—a protein classically known for its role in synaptic pruning during neural development and disease.

Microglia, often regarded as the brain’s resident macrophages, are pivotal players in shaping neural circuits by pruning synapses during development and in response to injury or disease. The newly characterized STING/C1q axis instigated by γδ T17 cells influences microglial behavior, skewing them towards heightened synaptic pruning activity. This excessive pruning is believed to underlie the synaptic dysfunction observed in SAE, which contributes to the cognitive and neurological impairments typical of the syndrome.

This finding establishes a mechanistic framework linking peripheral immune triggers in the gut to central nervous system pathology through a detailed immune signaling cascade. It underscores the underappreciated role of intestinal immune cells in modulating brain function during systemic inflammatory insults and highlights the brain-gut axis not merely as a neurochemical communication pathway but as an immunological highway.

Further, the male-specific exacerbation of SAE described by Wu et al. adds a critical dimension to our understanding of sex differences in immune responses and neuroinflammation. The study’s data suggest that male mice, compared to females, possess a distinct γδ T17 cell profile or activity level that predisposes them to more severe neuroimmune consequences during sepsis. This sex bias could reflect differences in hormonal regulation of immune cell function or genetic and epigenetic programming and raises important considerations for personalized therapeutic strategies.

The authors’ advanced use of immunohistochemistry, single-cell sequencing, and functional assays paints a comprehensive picture of this gut-brain immune axis. Their methods allowed precise delineation of γδ T17 cell migration, activation status, and cytokine milieu alongside microglial phenotypic changes after sepsis induction. This multi-modal experimental approach strengthens the causal link between small intestinal immune responses and brain microenvironment alterations.

Importantly, the discovery that the STING pathway is centrally involved offers a tantalizing therapeutic target. STING modulates expression of various inflammatory mediators and is implicated in multiple autoimmune and neurodegenerative diseases. Pharmacological modulation of STING signaling or downstream components such as C1q expression could potentially mitigate the detrimental microglial synaptic pruning that drives cognitive deficits in SAE.

Beyond clinical implications, this research redefines the broader conceptual landscape of neuroimmunology by illustrating how gut-derived immune cell subsets can deliberately influence the central nervous system’s immune milieu during systemic insults. It invites further exploration of other gut-resident immune populations and their potential roles in various neuropsychiatric and neurodegenerative conditions, particularly those associated with systemic inflammation or gut dysbiosis.

Moreover, the study’s detailed interrogation of cell signaling pathways invites a deeper investigation into the molecular triggers that initiate γδ T17 cell activation in the gut following sepsis. Understanding upstream signals—be they microbial products, tissue damage-associated molecules, or metabolic cues—may help identify early intervention points to curb the maladaptive neuroimmune cascade.

The intersection of complement biology with STING activation in microglial synaptic pruning also invites a renewed focus on how innate immune effectors traditionally studied in peripheral infections contribute to central nervous system dysfunction. Complement components, especially C1q, have long been associated with neurodegenerative diseases such as Alzheimer’s, and this study links them to acute neuroinflammatory contexts mediated by peripheral immunity.

Additionally, the authors’ emphasis on sex differences in immune-neural interactions highlights the importance of including both sexes in preclinical research, which historically skewed heavily towards male models or failed to address sex as a biological variable. The sexual dimorphism observed in the present study could illuminate broader principles governing immune-mediated neural pathology, with implications extending to human sepsis survivors who often exhibit sex-specific recovery trajectories.

While this study was conducted in murine models, its implications for human health are profound. Sepsis remains a leading cause of mortality worldwide, and SAE contributes significantly to post-sepsis morbidity. Current management focuses largely on supportive care, with no targeted therapies to prevent or reverse brain dysfunction. Insights into gut immune contributions to SAE pathophysiology may herald novel interventions that leverage immune modulation at peripheral sites to protect the brain.

Future research building on these findings may explore therapeutic strategies such as γδ T17 cell depletion, STING pathway inhibitors, or complement-targeted treatments to preserve synaptic architecture in the face of systemic infection. Additionally, microbiota-targeted therapies could modulate the intestinal immune environment to beneficially influence γδ T17 cell activity, further emphasizing the gut-brain axis’s importance for brain health during systemic insults.

Collectively, Wu, Zhang, Yu, et al.’s work offers a paradigm shift in understanding SAE and broadens the conceptual scope of neuroimmune interactions. By positioning small intestinal γδ T17 cells as pivotal modulators of microglial synaptic pruning via the STING/C1q axis, this research bridges the gap between peripheral inflammation and central nervous system dysfunction, paving the way for innovative therapeutic approaches that transcend traditional compartmentalization of immune and neurological disease.

Subject of Research: The role of small intestinal γδ T17 cells in promoting sepsis-associated encephalopathy (SAE) through STING/C1q-induced microglial synaptic pruning in male mice.

Article Title: Small intestinal γδ T17 cells promote SAE through STING/C1q-induced microglial synaptic pruning in male mice.

Article References:
Wu, Y., Zhang, Y., Yu, Y. et al. Small intestinal γδ T17 cells promote SAE through STING/C1q-induced microglial synaptic pruning in male mice. Nat Commun 16, 6779 (2025). https://doi.org/10.1038/s41467-025-62181-3

Image Credits: AI Generated